Reduction of LDL-C, Apo B & increase HDL-C in the management of hyperlipidemias including primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb).
AdultInitially 10 mg once daily. Patient requiring less aggressive LDL-C reductions, w/ predisposing factors to myopathy & Asian patient Initially 5 mg once daily. Patient w/ marked hypercholesterolemia & aggressive lipid targets Initially 20 mg once daily, may be increased to max: 40 mg once daily.
Myopathy. Perform LFTs prior to, 12 wk after initiation of therapy & semiannually thereafter. Asian patients. Not recommended in combination w/ gemfibrozil. Concomitant use w/ fibrates, niacin; drugs increasing plasma conc eg, certain PIs including combinations of ritonavir w/ atazanavir, lopinavir &/or tipanavir. Not to be used during pregnancy & lactation.
Sign Out
